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Abstract
Introduction—Prescription opioid pain reliever overdose is a major public health issue in the 
United States. To characterize the location of drug-related deaths, we examined fatal prescription 
opioid and illicit drug-related deaths reported in 12 states.
Methods—Data are from the Substance Abuse and Mental Health Services Administration's 
Drug Abuse Warning Network (DAWN). Medical examiners or coroners in 12 states (MA, MD, 
ME, NH, NM, OK, OR, RI, UT, VA, VT, WV) reported details of state-wide drug-related 
mortality during 2008–2010. DAWN data included location and manner of death, age, race, and 
drugs involved. Deaths were coded into three categories: prescription opioid-related, illicit drug-
related, and cases that involved both a prescription opioid and an illicit drug.
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Results—During a 3-year period, there were 14,091 opioid or illicit drug-related deaths in 12 
states. More than half of the prescription opioid-related deaths in all states, except Maryland, 
occurred at home, rather than in public or in a health care facility. Although it was still the 
predominant category, lower percentages of illicit drug-related deaths occurred at home.
Conclusion—Prescription opioid overdoses have increased substantially, and the location of the 
person at the time of death can have important public health implications for interventions.
Practical applications—This paper highlights that bystander support can be a critical 
lifesaving factor in drug related deaths but may be more likely for illicit drug-related deaths than 
for prescription opioid-related deaths.
Keywords
Drug Abuse Warning Network (DAWN); Mortality; Overdose; Opioid; Heroin
1. Introduction
Drug overdoses are a major public health issue in the United States (Paulozzi, 2012). 
Prescription opioid pain relievers (OPR) alone or in combination with benzodiazepines or 
other drugs account for nearly half of all drug overdose deaths (Jones, Mack, & Paulozzi, 
2013). The percentage increase in prescription OPR deaths since 1999 is startling—a 265% 
increase among men and a 415% increase among women (Mack, Jones, & Paulozzi, 2013).
The location of drug use, the presence of others at the scene, and the actions of bystanders 
(e.g., calling for help) could determine whether an overdose becomes a fatality (Darke & 
Zador, 1996). Certain location characteristics, such as homelessness (Fischer et al., 2004) or 
residential isolation, have been extensively characterized among cases of drug overdoses 
(Cooper, Friedman, Tempalski, & Friedman, 2007), although primarily among injection 
heroin users in poor urban areas. Among specific inner-city populations, the following 
characteristics predict fatal overdoses: a lack of permanent housing (Fischer et al., 2004; 
Jenkins et al., 2011), housing in poor physical condition (Hembree et al., 2005), residence in 
a low-income hotel (Davidson et al., 2003), using heroin while alone, (Davidson et al., 
2003), and using drugs in public (Dietze, Jolley, Fry, Bammer, & Moore, 2006) or in 
abandoned buildings (Bohnert, Tracy, & Galea, 2009).
There are differences in the population at highest risk of a prescription OPR overdose 
compared with those at highest risk of an illicit drug overdose (Mack et al., 2013; Paulozzi, 
2012). Further, the location of a fatal overdose varies by the type of drug involved. Illicit 
drug deaths, such as those involving heroin and cocaine, occurred more often in 
nonresidential, nonmedical locations. People dying of illicit drug overdoses appeared to be 
more likely than those dying of prescription OPR overdoses to die in a medical facility 
(Paulozzi, 2012). A study of overdose deaths in Connecticut found that 8.2% of OPR deaths 
occurred in public places compared to 19.7% of heroin-related deaths (Green, Grau, Carver, 
Kinzly, & Heimer, 2011). Describing situations in which drug users survive overdoses is 
important; understanding why others do not is critical. We know little about whether some 
determinants of survival (e.g., being alone, being inexperienced, concealing use from 
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bystanders) differ between prescription OPR and illicit drug users. A closer examination of 
the location of overdose deaths by type of drug (prescription OPR vs. illicit) for various risk 




The Substance Abuse and Mental Health Services Administration's (SAMHSA) public 
health surveillance system, the Drug Abuse Warning Network (DAWN), collected data on 
deaths investigated by participating medical examiners/coroners (ME/C) in selected states 
and metropolitan areas, which CDC received via special request to SAMHSA. The ME/C 
investigations included information gathered from crime scene reports, police reports, 
interviews with family and friends, and autopsy reports, including drug toxicology. DAWN 
cases were identified through a retrospective review of decedent case files in each 
participating death investigation jurisdiction. The completed investigation records were 
reviewed by a trained abstractor and data were submitted electronically to SAMHSA 
(Substance Abuse and Mental Health Services Administration, 2012).
2.2. Measures
Deaths involving prescription OPR1 or illicit drugs2 were examined for all 12 states that 
participated in the DAWN ME/C monitoring effort (2008–2010): Massachusetts, Maryland, 
Maine, New Hampshire, New Mexico, Oklahoma, Oregon, Rhode Island, Utah, Virginia, 
Vermont, and West Virginia (N = 14,091 deaths). If reported, marijuana, only legally 
available at the time in three of the states, was coded among illicit drugs. The ME/C records 
provided detailed information about all drug-related deaths; however, no drug doses were 
quantified. Cases were operationally defined as any death determined by the ME/C to be 
related to recent drug use in which OPRs or illicit drugs were involved. The drug use might 
have been for legitimate, therapeutic purposes or for the purpose of drug abuse or misuse. 
We were not able to determine whether decedents had a prescription for the drugs they 
ingested. Manner of death was coded by ME/C′s as suicide, homicide, natural, unintentional 
(accidental), or could not be determined, which was assigned by the ME/C when a definitive 
ruling was not possible. No personal identifying information was available in the database 
and this study did not require human subjects' review. To ensure anonymity, counts of deaths 
in a category in each year that were less than four were suppressed. In many subcategories, 
counts were low in a single year, so data from 3 years were combined for analysis, further 
protecting decedent identity. Low counts precluded analyses of trends across years by state. 
When they could be determined, the ME/Cs also submitted race or ethnicity in the case 
record.
1Prescription opioid drugs include buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, meperidine, 
methadone, morphine, nalbuphine, oxycodone, oxymorphone, propoxyphene, and narcotic analgesics not otherwise specified. 
Combination drugs were coded with opioid drug (e.g., acetaminophen/oxycodone was put in the oxycodone category).
2Illicit drugs include cocaine, heroin, marijuana, and methamphetamine.
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Location of death in the DAWN ME/C data set was initially coded by abstractors into one of 
six categories: (1) decedent's home (i.e., owned or leased, or long-term care facility); (2) 
emergency room (ER); (3) other health care facility (i.e., drug treatment); (4) public place; 
(5) other private location (i.e., hotel or motel) or car; or (6) unknown. The abstractors were 
given instructions to select other private location if the death occurred in a neighbor's house 
or in a car. Examples of public place included “in a store, on the street, or in a park.” 
Because they are conceptually similar, emergency room (ER) and other medical department 
or treatment facility cases were combined into one ER or health care facility category. 
Because of the small numbers in each set, three categories (i.e., public place, other private 
home or car, or unknown) were combined into one other or missing category. Manner of 
death and racial or ethnic categories of decedents were coded by the abstractors based on the 
records.
3. Results
During a 3-year period (2008–2010), 14,091 prescription OPR or illicit drug-related deaths 
occurred in 12 states at home (55.7%), at emergency room or health care facilities (27.8%), 
or in other or missing (16.5%) locations. The majority of the deaths (78.9%) were 
prescription OPR drug-related, either without illicit drugs (63.4%), or in combination with 
illicit drugs (15.4%).
There were similar patterns for location of death among white and Hispanic decedents in all 
three drug categories (Table 1). The majority of white OPR-related deaths occurred at home 
(62.0%); compared to 64.0% of Hispanic decedents; among white illicit drug drug-related 
decedents, the largest percentage was at home (45.2%); similar to Hispanic decedents 
(43.6%). Black OPR related deaths were equally distributed between a home location 
(44.0%) and an ER (44.3%); the largest percentage for illicit drug-related death was an ER 
location (46.3%). Among those aged 20 years or older, more than half of the prescription 
OPR related deaths occurred at home, and although the percentages are lower, the highest 
category for illicit and combination drug-related deaths was also at home. Among those 
younger than 20 years, the highest percentage category for OPR-related deaths was home 
(48.9%); and ER for illicit (36.1%) and combination drug-related deaths (44.2%). The 
highest percentage category was at home for each manner of death and drug type.
Overall, 61.3% of the prescription OPR-related deaths occurred at home, 25.3% in an ER or 
health care facility, and 13.4% in another location (Table 2). More than half of OPR-related 
deaths occurred at home in every state, except MD (49.0%). Although in most states, the 
highest percentage of illicit drug-related deaths occurred at home, the percentages were 
lower in each state for illicit drug-related deaths compared with prescription OPR-related 
deaths. Maryland and Massachusetts had a higher percentage of illicit drug-related deaths 
occurring at an ER (41.5%) than at home (MD = 35.3%; MA = 41.3%), and Oregon's 
highest category was other or missing (42.3%; 4.4% of which was a public place and 37.8% 
was other). For deaths where both prescription OPR and illicit drugs were involved, the 
highest category for location of death was at home, except in Maryland (ER was highest, 
44.4%) and Vermont (ER; 40.0%; other 40%).
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4. Discussion and conclusions
This study characterized drug-related deaths by state, age, race or ethnicity, manner of death, 
and location of death to help guide overdose prevention efforts. Among whites and 
Hispanics, for all three drug categories, the largest percentage of decedents died at home. 
The overall percent-age of deaths occurring in public or unknown places was low. In every 
state except Utah, a higher percentage of illicit drug-related deaths than prescription OPR-
related deaths occurred in an ER or health care facility. In all but one state (Maryland), the 
majority (>50%) of prescription OPR-related deaths happened at home. Black decedents (for 
prescription OPR and illicit drug categories) and those aged younger than 20 years (illicit 
and combination drugs) were also more likely to die within an ER or other health care 
facility.
The pharmacokinetics of opioids vary by drug and can vary even within a drug depending on 
route of administration (e.g., injection vs. oral administration). Death may occur rapidly 
depending upon potency and route of administration. Because users of illicit drugs often 
inject where they buy drugs, and signs of distress may appear rapidly, other users or 
strangers may notice that a victim is in distress. These other users, however, often do not call 
911 for help, perhaps fearing police intervention (Dietze et al., 2006; Tobin, Davey, & 
Latkin, 2005; Wagner et al., 2015), but instead they may slap or pinch the victim, give them 
coffee, try to make them walk, inject them with a different substance (e.g., cocaine, salt, 
water), administer naloxone, or attempt CPR (Baca & Grant, 2005; Bohnert, Tracy, & Galea, 
2012; Wagner et al., 2015). Researchers studying inner city illicit drug use have suggested 
that efforts to prevent overdose (i.e., good Samaritan laws or increased access to naloxone) 
could focus on those persons using drugs in public or in abandoned buildings (Bohnert et al., 
2009). Prescription OPRs, however, are most often taken orally, absorbed slowly and 
variably, and with toxicity escalating gradually, perhaps after potential bystanders depart 
(Baca & Grant, 2005). In private homes, overdose prevention may fall to different groups of 
bystanders, friends, relatives, or caregivers, or their responses may differ. For instance, in 
private locations, which would include homes, bystanders may not call for emergency 
services after giving naloxone (Lankenau et al., 2013). Given the short duration of action of 
naloxone, a return of opioid intoxication from an OPR with a longer duration of action, 
might then lead to fatal rebound respiratory distress.
The percentage of prescription OPR-related deaths occurring at home generally increased 
with age, rising to more than two-thirds among those aged 50 years or older. Age and 
residential status are closely related, perhaps decreasing the chance of overdose witnesses as 
age increases. In the United States in 2013, 15% of those younger than 20 years and 21.5% 
of those aged 45–54 years or older lived alone (U.S. Census Bureau, 2013). As people age, 
they are more likely to live alone and spend more time alone, which may increase their 
chances of having an unwitnessed drug overdose.
This study has several limitations. We were unable to distinguish between decedents who 
had a prescription for an OPR and those who acquired them in other ways. Further, the data 
do not indicate the location where the drug was taken, the amount consumed, whether 
bystanders were present in the home, or whether bystanders (e.g., family or housemates) 
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knew the drug(s) were taken. These five pieces of information would greatly enhance the 
ability to understand the circumstances of the fatal event. Given increasing public awareness 
about naloxone and increased access to it in the United States, it would also be useful to 
know whether anyone in a household had access to it.
In addition, assigning responsibility to one drug in multidrug deaths is a challenge. Non-
opioid prescription drugs were also reported by ME/Cs (e.g., alprazolam, diazepam, 
benzodiazepines), and they were sometimes taken in combination with prescription opioids, 
but not in sufficient quantity to present as a separate analytic category. Thus, any of the cases 
coded into the three drug categories used in this analysis (prescription opioids, illicit drugs, 
prescription opioids, and illicit drugs) could have involved other prescription, illicit, or over 
the counter drugs. The drugs involved in deaths might not all have been identified and 
documented. DAWN ME/C does not rely on a statistical sampling of MEs, and findings 
cannot be considered representative of ME/Cs who did not participate, and results cannot be 
extrapolated to the entire United States (Substance Abuse and Mental Health Services 
Administration, 2012). State laws dictate which deaths are subject to ME review, and these 
laws vary by state. Finally, toxicology testing practices can vary depending on local 
concerns, funding, and testing technology, which affects the number of deaths determined to 
be DAWN ME/C cases and the number of deaths attributed to particular drugs. It is likely 
that our results undercount the number of drug-related deaths.
Consideration of home-based interventions for prescription OPR pain reliever overdoses is a 
prudent public health strategy. On-site interventions, such as naloxone administration, rescue 
breathing, or calling 911, are clearly most useful when someone is there to administer them 
(Clark, Wilder, & Winstanley, 2014; Enteen et al., 2010). Naloxone given by first responders 
can reverse the effects of the opioid taken with high efficacy (Vilke, Sloane, Smith, & Chan, 
2003), but even the administration of CPR by a bystander before an ambulance arrives can 
decrease hospitalizations among nonfatal cases (Dietze, Cantwell, & Burgess, 2002). 
SAMHSA's Opioid Overdose Toolkit (http://store.samhsa.gov/shin/content//SMA14-4742/
Overdose_Toolkit.pdf) provides individuals and communities with information about 
preventing opioid-related overdose deaths and the U.S. Department of Health & Human 
Services offers a federal resource (www.hhs.gov/opioids) of tools and information for 
families, health care providers, law enforcement, and other stakeholders about prescription 
drug abuse and heroin use prevention, treatment, and response.
Patients and physicians can also take steps to reduce prescription OPR overdose deaths. 
Patients need to discuss all medications they are taking with their health care provider, use 
prescription drugs only as directed, store them in a secure place, and get help for substance 
abuse problems (National Treatment Referral Helpline 1-800-662-HELP [4357]). Physicians 
can discuss all pain treatment options, including ones that do not involve prescription drugs, 
as well as the risks and benefits of taking prescription painkillers. Physicians can follow 
guidelines for prescribing painkillers responsibly (http://www.cdc.gov/drugoverdose/
prescribing/guideline.html), including the following: screening and monitoring for substance 
abuse and mental health problems; prescribing only the quantity needed on the basis of 
appropriate pain diagnosis; using patient–provider agreements combined with urine drug 
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tests for people who use prescription painkillers long-term; and avoiding combinations of 
prescription painkillers and benzodiazepines unless there is a specific medical indication.
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Table 1
Location of drug-related deaths by demographics and manner of death, Drug Abuse Warning Network 









































 White 62.0 (4979) 24.6 (1979) 13.4 (1073) 45.2 (993) 30.1 (661) 24.7 (543) 50.5 (894) 30.6 (541) 18.9 (334)
 Black 44.0 (169) 44.3 (170) 11.7 (45) 33.8 (158) 46.3 (216) 19.9 (93) 41.4 (84) 38.4 (78) 20.2 (41)
 Hispanic 64.0 (231) 21.1 (76) 15.0 (54) 43.6 (105) 32.0 (77) 24.5 (59) 55.1 (97) 27.3 (48) 17.6 (31)
 Other/missing 62.0 (101) 21.5 (35) 16.6 (27) 25.0 (17) 38.2 (26) 36.8 (25) 51.6 (16) 29.0 (9) 19.4 (6)
Age group (years)
 0–19 48.9 (115) 37.4 (88) 13.6 (32) 34.0 (33) 36.1 (35) 29.9 (29) 30.2 (13) 44.2 (19) 25.6 (11)
 20–29 52.0 (792) 31.0 (472) 17.0 (259) 40.1 (250) 32.6 (203) 27.3 (170) 43.8 (227) 35.3 (183) 20.8 (108)
 30–39 57.2 (1108) 29.0 (562) 13.7 (266) 39.7 (265) 33.1 (221) 27.1 (181) 45.8 (240) 34.5 (181) 19.7 (103)
 40–49 64.3 (1669) 22.4 (580) 13.3 (346) 42.5 (375) 35.5 (313) 22.0 (194) 54.4 (370) 27.2 (185) 18.4 (125)
 50–59 68.2 (1383) 20.3 (411) 11.6 (235) 49.4 (291) 29.5 (174) 21.1 (124) 57.1 (216) 26.5 (100) 16.4 (62)




 Suicide/homicide 65.8 (612) 19.1 (178) 15.1 (140) 53.8 (78) 20.0 (29) 26.2 (38) 68.5 (50) 13.7 (10) 17.8 (13)
 Unintentional 61.6 (3931) 24.4 (1558) 13.9 (889) 43.1 (944) 32.2 (704) 24.7 (540) 50.6 (817) 30.1 (486) 19.3 (312)
 Undetermined 57.4 (937) 32.1 (524) 10.4 (170) 39.2 (251) 38.6 (247) 22.2 (142) 45.6 (224) 36.7 (180) 17.7 (87)
a
Opioid drugs = buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, nalbuphine, 
oxycodone, oxymorphone, propoxyphene, and narcotic analgesics not otherwise specified.
b
Illicit drugs = cocaine, heroin, marijuana (if reported), and methamphetamine.
c
Suppressed due to low count.
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Table 2
Location of drug related death by drug class and state, Drug Abuse Warning Network Medical Examiner, 
2008–2010 (n = 14,091).
Location
Home Row% (n) ER or health care facility Row% (n) Other or missing Row% (n)
Prescription opioid
a
 Massachusetts 52.3 (641) 33.4 (409) 14.3 (175)
 Maryland 49.0 (478) 38.1 (372) 12.9 (126)
 Maine 65.2 (223) 22.8 (78) 12.0 (41)
 New Hampshire 65.1 (179) 24.0 (66) 10.9 (30)
 New Mexico 72.2 (539) 14.6 (109) 13.3 (99)
 Oklahoma 68.1 (906) 21.5 (286) 10.4 (138)
 Oregon 65.4 (450) 16.6 (114) 18.0 (124)
 Rhode Island 58.9 (168) 28.8 (82) 12.3 (35)
 Utah 68.3 (528) 22.1 (171) 9.6 (74)
 Virginia 61.9 (723) 25.1 (293) 13.0 (152)
 Vermont 66.1 (82) 25.8 (32) 8.1 (10)
 West Virginia 56.0 (563) 24.7 (248) 19.4 (195)
All states 61.3 (5480) 25.3 (2260) 13.4 (1199)
Illicit drug
b
 Massachusetts 41.3 (198) 41.5 (199) 17.3 (83)
 Maryland 35.3 (183) 41.5 (215) 23.2 (120)
 Maine 33.3 (7) 33.3 (7) 33.3 (7)
 New Hampshire 51.4 (37) 30.6 (22) 18.1 (13)
 New Mexico 48.0 (147) 29.1 (89) 22.9 (70)
 Oklahoma 44.0 (103) 40.2 (94) 15.8 (37)
 Oregon 37.6 (187) 20.1 (100) 42.3 (210)
 Rhode Island 48.1 (52) 41.7 (45) 10.2 (11)
 Utah 62.2 (117) 20.2 (38) 17.6 (33)
 Virginia 46.2 (169) 31.4 (115) 22.4 (82)
 Vermont 44.4 (8) 27.8 (5) 27.8 (5)
 West Virginia 39.4 (65) 30.9 (51) 29.7 (49)
All states 42.8 (1273) 33.0 (980) 24.2 (720)
Both opioid and illicit
 Massachusetts 45.3 (266) 36.1 (212) 18.6 (109)
 Maryland 38.7 (117) 44.4 (134) 16.9 (51)
 Maine 50.0 (11) 31.8 (7) 18.2 (4)
 New Hampshire 50.0 (19) 31.6 (12) 18.4 (7)
 New Mexico 59.8 (131) 19.2 (42) 21.0 (46)
 Oklahoma 57.4 (62) 25.9 (28) 16.7 (18)
 Oregon 56.0 (121) 19.4 (42) 24.5 (53)
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Location
Home Row% (n) ER or health care facility Row% (n) Other or missing Row% (n)
 Rhode Island 61.2 (52) 24.7 (21) 14.1 (12)
 Utah 62.3 (170) 22.3 (61) 15.4 (42)
 Virginia 50.0 (73) 34.2 (50) 15.8 (23)
 Vermont
– 
c 40.0 (6) 40.0 (6)
 West Virginia 39.3 (66) 36.3 (61) 24.4 (41)
All states 50.0 (1091) 31.0 (676) 18.9 (412)
a
Opioid drugs = buprenorphine, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, nalbuphine, 
oxycodone, oxymorphone, propoxyphene, and narcotic analgesics not otherwise specified.
b
Illicit drugs = cocaine, heroin, marijuana (if reported), and methamphetamine.
c
Suppressed due to low count.
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